Prenatal Iron and autism spectrum disorder (ASD) risk reduction
A research team lead by Dr. Rebecca J. Scmidt at the University of California Davis Department of Public Health Sciences in the School of Medicine (MIND Institute) has identified a link between insufficient maternal iron intake and Autism Spectrum Disorder (ASD) as a part of the CHARGE (Childhood Autism Risks from Genetics and Environment) Study.
The researchers evaluated daily iron intake from a variety of sources, including supplements, during the three months preceding pregnancy, through gestation and during breastfeeding. The authors report that mothers of children with ASD were less likely to report taking iron-containing supplements during the study period. Similarly, those mothers in the highest quintile of iron intake were associated with a reduced risk of ASD, particularly during the breastfeeding interval. This finding is significant, given that nearly half of all expectant mothers have inadequate iron intake during pregnancy. Often, this is due to the discomfort and GI distress that accompanies prenatal supplements prepared with inorganic mineral salts. A properly prepared iron chelate such as Ferractiv – clinically shown to reduce uncomfortable side effects – may be helpful in overcoming these complaints, opening the possibility to better pregnancy outcomes.
This work was published online September 22 in the American Journal of Epidemiology.
Biotron's mission is focused on improving and producing scientifically validated mineral chelates and complexes that are highly compatible with human physiology.